Work

Pharmacogenomic Study of Carfilzomib in Relapsed/Refractory Multiple Myeloma Suggests That Carfilzomib Is a More Potent Proteasome Inhibitor Than Bortezomib

Year: 2012

Type: article

Source: Blood

DOI: 10.1182/blood.v120.21.5015.5015

Authors: Qing Zhang, Christoph Heuck, Ya-Wei Qiang, Frits van Rhee, Sarah Waheed, Clyde Bailey, Susan B. Panozzo, Joshua Epstein, Bart Barlogie, Saad Z Usmani

Institution: University of Arkansas for Medical Sciences

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2566744363

FWCI:

Cites:

Cited by: 1

Related to: 10